Stock Alert: NeuroMetrix More Than Doubles

By RTTNews Staff Writer   ✉   | Published:

Shares of NeuroMetrix, Inc. (NURO) are currently surging over 100% despite no stock related news.

NURO is currently trading at $4.56, up $2.41 or 112.093%, on the Nasdaq.

NeuroMetrix, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders.

The company has three FDA cleared commercial products. DPNCheck, a point-of-care test used to evaluate peripheral neuropathies, ADVANCE, a point-of-care device used as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies, and Quell 2.0, a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain that is available over-the-counter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
There has been continued business deterioration across the restaurant industry, with restaurant closures and bankruptcies continuing to rise across the U.S. and job losses growing at some of the prominent restaurants, according to a new survey by the National Restaurant Association or NRA. The survey details were shared by the NRA in a letter to the Congressional leadership. DISH Network LLC, a unit of Dish Network Corp., has agreed with the Department of Justice and four states to pay $210 million in penalties to settle telemarketing violations suit. In a statement, the Justice Department said the direct-broadcast satellite provider will pay $126 million in civil penalties to the United States. The company allegedly placed millions of telemarketing calls. Canada has secured an agreement with Pfizer to begin early delivery of doses of Pfizer-BioNTech's COVID-19 vaccine, Canadian Prime Minister Justin Trudeau revealed in a tweet. The news comes as UK became the first Western country to start mass vaccination against Covid-19 with the Pfizer vaccine today.